34 - Are Transplant Patients Human Epicenters of Viral Variants and Resistance?

Thursday, September 30, 2021

3:45 PM - 5:00 PM EDT

Moderator(s)

Pearlie Chong, MD, MSCR

Assistant Professor of Medicine
University of Texas Southwestern
Dallas, TX, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.
Michael Ison, MD MS

Professor of Medicine (Infectious Diseases) and Surgery (Organ Transplantation)
Infectious Diseases and Organ Transplantation
Northwestern University
Chicago, IL, United States

GlaxoSmithKlein (Individual(s) Involved: Self): Grant/Research Support

Speaker(s)

Adam Lauring, MD, PhD

Associate Professor
Internal Medicine, Microbiology and Immunology
University of Michigan
Ann Arbor, MI, United States

Bio-Rad (Individual(s) Involved: Self): Honorarium, Other Financial or Material Support; Roche (Individual(s) Involved: Self): Consultant, Paid member of clinical trial steering committee; Sanofi (Individual(s) Involved: Self): Consultant
Kim Green, PhD

Sr. Investigator
National Institutes of Health
Bethesda, MD, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.
Alpana Waghmare, MD

Assistant Professor
Univ of Washington, Seattle Children’s, Fred Hutchinson Cancer Center
Seattle, WA, United States

Allovir (Individual(s) Involved: Self): Scientific Research Study Investigator; Ansun Biopharma (Individual(s) Involved: Self): Scientific Research Study Investigator; Kyorin Pharmaceuticals (Individual(s) Involved: Self): Advisor or Review Panel member; Pfizer (Individual(s) Involved: Self): Scientific Research Study Investigator

Participants should be aware of the following financial/non-financial relationships:

Pearlie P. Chong, MD, MSCR: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Michael G. Ison, MD MS: GlaxoSmithKlein (Individual(s) Involved: Self): Grant/Research Support

Adam S. Lauring, MD, PhD: Bio-Rad (Individual(s) Involved: Self): Honorarium, Other Financial or Material Support; Roche (Individual(s) Involved: Self): Consultant, Paid member of clinical trial steering committee; Sanofi (Individual(s) Involved: Self): Consultant

Kim Y. Green, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Alpana Waghmare, MD: Allovir (Individual(s) Involved: Self): Scientific Research Study Investigator; Ansun Biopharma (Individual(s) Involved: Self): Scientific Research Study Investigator; Kyorin Pharmaceuticals (Individual(s) Involved: Self): Advisor or Review Panel member; Pfizer (Individual(s) Involved: Self): Scientific Research Study Investigator

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit

No CPE credits

Learning Objectives:

At the conclusion of this session, participants will be able to:

review current mechanisms of emergence of viral variants in immunosuppressed patients, reviewing studies (where available) in transplant patients
discuss implications of these viral variants in development of resistance and transmission of infection
discuss role of viral variant sequencing in clinical care

Presentations:

Are Immunosuppressed Patients the Source of Emerging Genetic Variants to sars-cov-2?
Speaker: Adam S. Lauring, MD, PhD – University of Michigan
Chronic Norovirus Infections in Transplant Patients
Speaker: Kim Y. Green, PhD – National Institutes of Health
Prolonged Shedding of Respiratory Viruses: Influenza, RSV and Parainfluenza
Speaker: Alpana Waghmare, MD – Univ of Washington, Seattle Children’s, Fred Hutchinson Cancer Center